Group items tagged

French drugmaker Sanofi said on Monday (June 13) an upgraded version of the Covid-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot. While the two companies' first experimental Covid shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is moulded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations. Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna. In a separate trial conducted by a French hospitals network, Sanofi's Beta-adapted booster shot triggered a higher immune response than Sanofi's first-generation shot or Pfizer-BioNTech's established vaccine in previously vaccinated volunteers.

Provision of free lateral flow tests could end in the UK, and prime minister Boris Johnson is expected to make the big announcement within weeks, The Sunday Times has reported. The report said that in future free test kits could be provided only in high-risk settings such as care homes, hospitals and schools, and to people with symptoms, and contact tracing by NHS Test and Trace is also expected to be scaled back. The newspaper quoted a senior Whitehall source as saying: "I don't think we are in a world where we can continue to hand out free lateral flow tests to everybody. "It's likely we will move to a scenario where there is less testing, but we have a capacity to ramp it up if necessary." It added that more than £6 billion of public money has already been spent on mass testing. Separately, Dr Clive Dix, former chairman of the country's vaccine task force said that Covid-19 should now be treated as a flu, and mass vaccination campaigns should end after the booster shots in the UK.

Aspire Pharma has completed the acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India); speciality generic pharmaceutical organisations. Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire's. "We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally," said Richard Condon, Chief Executive Officer of Aspire Pharma.

After I have finished playing some casino games, using my, Juicy Stakes Casino bonuses, I am hungry. What should I eat? A juicy steak (wink, wink)? Fried chicken? An Ingestible Pill? Wait, what? What is an ingestible pill? Is that a food or vitamin? Actually, it is neither. It is new technology developed by Pfizer. Pfizer is the pharmaceutical company that gave us the COVID vaccines that do not provide lifetime immunity to COVID or even prevent you from getting it in the short term. Pfizer is also the company that created the COVID medicine Paxlovid, which cause Biden to get a rebound COVID right after he supposedly recovered from COVID. Ingestible Pills are a version of a digital pill A digital pill is also known as a smart pill or an ingestible sensor. It is a pharmaceutical dosage form that contains an ingestible sensor inside of a pill. The sensor begins transmitting medical data after it is consumed. This pill and its other related technology are considered Digital Medicine. The purpose of the sensor is to determine if a person is taking their medicine or they are not taking their medicine. In other words, is the patient complying with taking their medicine or are they not complying with taking their medicine?

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

Alliance Healthcare, the UK's largest pharmaceutical wholesaler, has pledged to support the global efforts to cut carbon emissions, as set out at the recent UN Climate Change Conference, COP26. The company's pledge is in line with its aim to create "healthier futures and thebusiness", on which it has been working on for years. It aims to become the most sustainable independent full-line pharmaceutical wholesaler in the UK by 2030, ensuring to remain the sustainable partner of choice for its customers and manufacturers.

The World Health Organization called for caution on Tuesday (May 16) in using artificial intelligence for public healthcare, saying data used by AI to reach decisions could be biased or misused. The WHO said it was enthusiastic about the potential of AI but had concerns over how it will be used to improve access to health information, as a decision-support tool and to improve diagnostic care. The WHO said in a statement the data used to train AI may be biased and generate misleading or inaccurate information and the models can be misused to generate disinformation. It was "imperative" to assess the risks of using generated large language model tools (LLMs), like ChatGPT, to protect and promote human wellbeing and protect public health, the U.N. health body said.

The Royal Pharmaceutical Society (RPS) has said that it strongly supports the UK government's proposal that individuals born on or after 1 January 2009 should be prohibited from legally purchasing tobacco products. It has also shown its agreement to several other actions proposed by the Department of Health and Social Care's (DHSC) for 'Creating a Smokefree Generation and Tackling Youth Vaping' including: The inclusion of all tobacco products, cigarette papers, and herbal smoking products in the new legislation. Restrictions on the sale and supply of disposable vapes, and vape flavours. RPS President, Professor Claire Anderson, said: "Our recommendations reflect a commitment to creating a future free from the harms of tobacco and youth vaping. It's crucial to prohibit access for the youngest generation, regulate all tobacco-related items, and address the allure of flavoured e-cigarettes."

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted. The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is "no progress in improving diagnosis rates." At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed. Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations. Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.

The number of people living to be 100 or more increased by 3.7 per cent in England and Wales in 2022, compared to the previous year, according to new figures from the Office for National Statistics (ONS). ONS data also revealed that the number of centenarians in the UK has more than doubled in the last two decades. Wales has more centenarians (27 people per 100,000 aged 100 or over) than England (25 people per 100,000). It's good news that more people are living into their second century, but it also means that we may need to rethink our health plans for a longer future, a leading testing expert has suggested.

The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical associates to expand their roles in the NHS. This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said. Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated healthcare professionals once the regulations come into force, which is expected at the end of 2024. The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.

A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer's disease. The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said. Alzheimer's Research UK, the Alzheimer's Society and the National Institute of Health and Care Research have jointly launched the project. Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK, said that the NHS doesn't possess the "required levels of diagnostic infrastructure" to cope with the "growing demand" for dementia diagnosis. "Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this," she added.

The National Health Service (NHS) is embracing new technology and innovations like artificial intelligence (AI) to reduce the number of missed hospital appointments and improve waiting times for elective care. Following a successful pilot in Mid and South Essex NHS Foundation Trust, the health service is set to roll out AI software to 10 more trusts across England in the coming months. The software, developed by Deep Medical in collaboration with a frontline worker and NHS clinical fellow, helps reduce the number of missed appointments by offering patients convenient time slots and backup booking options. Since the AI programme was piloted six months ago, Mid and South Essex NHS Foundation Trust has seen a 30 per cent fall in non-attendances. During the pilot period, a total of 377 did not attends (DNAs) were prevented and an additional 1,910 patients were attended.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

NHS England has urged women to accept cervical screening invites to make it possible to eliminate the disease within the next two decades. Screening using a highly effective test helps detect human papillomavirus (HPV), which is responsible for over 99 per cent of all cervical cancers. Sadly, three in ten of those eligible for screening do not take up the potentially life-saving offer, as shown by the NHS Cervical Screening Programme, England 2022-2023 annual report. The report, published by NHSE on Thursday, showed that a total of 4.62 million women aged 25 to 64 for cervical screening was invited to book an appointment in 2022-23, and 3.43 million attended the screening.